Egrifta (Tesamorelin) Geriatric (65+): School and Activity Considerations

What Tesamorelin Does in the Aging Body

Tesamorelin is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors and triggers pulsatile release of growth hormone, which then drives hepatic production of insulin-like growth factor 1 (IGF-1). In younger adults, this mechanism is fairly predictable. In adults over 65, the pituitary somatotroph cells are less numerous and the GH axis is already blunted by age-related somatopause, so the drug's effect on IGF-1 levels can be more variable. [1, 2]

Somatopause and Why It Matters for Dosing

Natural GH secretion declines roughly 14% per decade after age 30. [1] By the time a patient reaches 65, basal IGF-1 may already sit in the low-normal or below-normal range. Tesamorelin at the standard 2 mg dose can push IGF-1 into the upper-normal or even supraphysiologic range in some older patients, which increases adverse-effect risk. Clinicians should obtain a baseline IGF-1 before prescribing and target a post-treatment level that remains within the age-adjusted normal range, not simply within the broad population normal. [2]

Visceral Adiposity Reduction: What the Trials Show

The key phase III trials (LIPO-010 and LIPO-011, combined N=816 HIV-positive adults) demonstrated that tesamorelin 2 mg daily reduced visceral adipose tissue (VAT) by approximately 15-18% at 26 weeks, compared with a roughly 5% reduction in the placebo arm (P<0.001). [3] The trials enrolled adults aged 18-65; geriatric-specific sub-group analyses were limited, but patients in the upper quartile of age still showed meaningful VAT reduction, suggesting the mechanism remains active in older adults.

Physical Activity Recommendations for Older Adults on Tesamorelin

Physical activity and tesamorelin interact in several clinically meaningful ways. Exercise independently raises GH pulse amplitude. Combining regular aerobic and resistance training with tesamorelin may therefore amplify IGF-1 elevation. For most patients that is a benefit. For older adults already at the top of the age-adjusted IGF-1 reference interval, it calls for closer monitoring. [4]

Aerobic Exercise: Type, Frequency, and Intensity

Low-impact aerobic activity, specifically walking, cycling on a stationary bike, swimming, or water aerobics, is the preferred starting point for adults 65 and older on tesamorelin. The American Heart Association recommends at least 150 minutes per week of moderate-intensity aerobic activity for older adults. [5] That target remains appropriate here. High-impact options like running on pavement add mechanical joint stress that can worsen the arthralgia tesamorelin sometimes causes, particularly in the knees and wrists.

A reasonable progression for a newly started geriatric patient:

• Weeks 1-4: 20-30 minutes of walking or water aerobics, 4-5 days per week, at a rating of perceived exertion (RPE) of 11-13 on the Borg 6-20 scale.
• Weeks 5-12: Increase duration to 35-45 minutes. Add one session of light resistance training per week.
• Month 4 onward: Two to three resistance sessions per week alongside 150+ minutes of aerobic activity, adjusting based on joint comfort and IGF-1 trends.

Resistance Training and Lean Mass

Tesamorelin improves lean body mass modestly. In the phase III program, lean mass increased by approximately 1.3 kg at 26 weeks in the treatment arm vs. Roughly 0.4 kg in the placebo group. [3] Resistance training amplifies that lean-mass response. For older adults at risk of sarcopenia, this is a clinically useful interaction. Programs should begin at 50-60% of one-repetition maximum and progress cautiously, given that fluid retention from GH stimulation can temporarily affect joint mechanics. [6]

Fall Risk: A Separate, Explicit Consideration

Falls are the leading cause of injury death in adults aged 65 and older in the United States. [7] Tesamorelin's adverse-effect profile includes peripheral edema (occurring in roughly 6% of patients in controlled trials), paresthesias, and arthralgia. Any of these can subtly impair balance and gait. Providers should perform a baseline fall-risk assessment using a validated tool such as the CDC STEADI algorithm before starting therapy, and repeat it at 3 months. [7]

Patients who score as high fall risk on STEADI should delay high-fall-risk activities, including ladder climbing, uneven-terrain hiking, or contact sports, until their edema and any paresthesias have stabilized. Balance training exercises, such as single-leg stands and tai chi, can be incorporated as a protective measure even in the first month of therapy.

Glucose Metabolism, Diet, and the Geriatric Patient

Impaired Glucose Tolerance Risk

Growth hormone is counter-regulatory to insulin. Tesamorelin-driven GH elevation raises fasting glucose and may worsen insulin sensitivity. In the phase III trials, new-onset diabetes or worsening hyperglycemia occurred in a small but non-trivial percentage of patients on active drug vs. Placebo. [3] In adults over 65, baseline insulin resistance is already higher; the American Diabetes Association notes that 26.8% of U.S. Adults aged 65 and older had diagnosed diabetes as of 2020. [8]

Fasting glucose and HbA1c should be obtained at baseline and reassessed at 3 months. If HbA1c rises by 0.4% or more, a formal diabetes management review is warranted before continuing tesamorelin. Patients should be counseled to reduce refined carbohydrate intake and maintain physical activity, both of which partially offset the GH-mediated glucose effect. [8]

Dietary Protein and Lean Mass Maintenance

Older adults generally need higher dietary protein per kilogram of body weight than younger adults to maintain lean mass, with many geriatric nutrition guidelines citing 1.2-1.6 g/kg/day as a reasonable target. [6] The combination of adequate protein intake and tesamorelin-stimulated IGF-1 may produce additive lean-mass benefits, though direct trials in the 65+ HIV-positive population confirming this additive effect are lacking.

Cognitive and Psychosocial Considerations

IGF-1 and Brain Health in Older Adults

IGF-1 receptors are present throughout the central nervous system. Observational data suggest that age-related IGF-1 decline correlates with cognitive decline, though causality has not been established in randomized controlled trials. [9] A 2019 analysis published in the Journal of Clinical Endocrinology and Metabolism (JCEM) examined IGF-1 trajectories in a cohort of 1,012 older adults and found that individuals in the lowest IGF-1 quartile had a 23% higher rate of incident cognitive impairment over 8 years compared with those in the middle two quartiles (adjusted hazard ratio 1.23, 95% CI 1.04-1.45). [9]

Tesamorelin's ability to restore IGF-1 toward the normal range in aging HIV-positive adults may therefore carry potential cognitive-health implications, though this has not been tested in a dedicated geriatric RCT. Providers should not represent this as a proven cognitive benefit to patients, but they should document baseline cognitive status using a validated screen such as the Montreal Cognitive Assessment (MoCA) so that any changes over time can be tracked.

Social Engagement and Group Activities

HIV-positive older adults experience disproportionate rates of social isolation. [10] Improvements in body composition from tesamorelin, including reduction of abdominal and dorsocervical fat accumulation, have been reported to improve body image and social confidence in clinical surveys, though formal quality-of-life trials specifically in the 65+ age group are limited. [3]

Group exercise programs, community walking clubs, senior fitness classes, and aquatic therapy all offer both physical and social benefits. These settings are appropriate and encouraged for patients who have been on stable tesamorelin therapy for 8 or more weeks and whose edema, if any, has resolved or stabilized. Providers should explicitly discuss these options at follow-up visits rather than leaving activity guidance as an afterthought.

Monitoring Protocol for Geriatric Patients on Tesamorelin

Baseline Workup Before Starting

Every geriatric patient starting tesamorelin should have the following before the first injection:

• IGF-1 (age- and sex-adjusted reference range)
• Fasting glucose and HbA1c
• Complete metabolic panel (renal and hepatic function)
• Fasting lipid panel (tesamorelin reduces triglycerides, which is a secondary benefit worth tracking)
• Body weight and waist circumference
• Fall-risk assessment (CDC STEADI or equivalent)
• MoCA or MMSE cognitive screen
• Blood pressure (edema risk monitoring)

On-Therapy Monitoring Schedule

The Endocrine Society's clinical practice guideline on growth hormone deficiency recommends IGF-1 monitoring every 6 months for adults on GH-axis therapies. [2] For adults over 65, a more conservative schedule of IGF-1 at 6 weeks, 3 months, and then every 6 months is appropriate given the greater variability in GH axis responsiveness in this population.

If IGF-1 exceeds the upper limit of the age-adjusted normal range at any point, the dose should be reduced or therapy held temporarily until levels normalize. Continuing therapy with a supraphysiologic IGF-1 increases the theoretical risk of promoting cell proliferation, which is particularly relevant in a population with a background prevalence of HIV-associated malignancies. [11]

Adverse Effects Most Likely to Affect Activity Participation

| Adverse Effect | Frequency (Phase III) | Impact on Activity | Management | |---|---|---|---| | Arthralgia | ~13% | Reduces weight-bearing tolerance | Low-impact activity, anti-inflammatory measures | | Peripheral edema | ~6% | Impairs balance, tightens footwear | Leg elevation, sodium restriction, reassess dose | | Paresthesias | ~4% | May affect grip and proprioception | Dose timing, neurologic evaluation if persistent | | Myalgia | ~4% | Limits resistance training progression | Gradual load increases, adequate protein and hydration | | Hyperglycemia | ~2-3% | Fatigue, thirst during exercise | Glucose monitoring, dietary adjustment |

Data derived from the combined phase III tesamorelin trial program. [3]

Drug Interactions Relevant to Active Older Adults

Older adults polypharmacy is the norm, not the exception. Several drug classes interact meaningfully with tesamorelin in the context of activity. [12]

Corticosteroids

Systemic corticosteroids inhibit the GH axis at the pituitary level and can blunt tesamorelin's effect on IGF-1. Many older HIV-positive patients receive inhaled or short-course oral corticosteroids. Providers should note that IGF-1 response may be attenuated during corticosteroid courses and avoid interpreting a low IGF-1 during steroid treatment as a reason to increase tesamorelin dose. [2]

Antiretroviral Agents

Protease inhibitors (PIs) such as ritonavir and lopinavir impair glucose metabolism independently, compounding tesamorelin's glucose effects. For older adults on PI-based regimens who are also exercising, glucose monitoring before and after prolonged sessions (>45 minutes) during the first 3 months of tesamorelin therapy provides useful safety data. [12]

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Short-term NSAID use for tesamorelin-related arthralgia is common but carries heightened cardiovascular and renal risk in adults over 65. [13] The American Geriatrics Society's Beers Criteria explicitly flags NSAIDs as potentially inappropriate in older adults, particularly those with renal impairment or a history of peptic ulcer disease. [13] Acetaminophen (up to 3 g/day in patients without hepatic disease) or topical diclofenac gel are preferred first-line options for joint pain management in this group.

Practical Guidance for Clinicians: A Decision Framework

The following clinical logic applies when assessing activity readiness in a geriatric tesamorelin patient:

1. Confirm IGF-1 is within the age-adjusted normal range. Activity amplifies GH pulse; if IGF-1 is already at the upper limit before activity is added, recheck in 4 weeks after exercise initiation.

2. Rule out active edema before recommending weight-bearing exercise. Even mild ankle edema changes gait mechanics and raises fall risk.

3. Screen for neuropathy. HIV-associated distal sensory neuropathy, present in up to 30-50% of long-term treated HIV patients, [14] impairs proprioception independent of tesamorelin. Falls in this population may reflect neuropathy as much as drug adverse effects.

4. Document baseline HbA1c. A value above 7.0% at baseline requires coordination with the patient's diabetes care team before adding the glucose-dysregulating effect of tesamorelin.

5. Revisit activity recommendations at every follow-up. What was appropriate at month 1 may need revision at month 6 as body composition shifts, joint pain resolves, and lean mass improves.

Special Populations Within the 65+ Group: Ages 75 and Older

Very limited data exist specifically for adults aged 75 and older on tesamorelin. The phase III trials did not enroll sufficient numbers in this age band to draw sub-group conclusions. A conservative approach is appropriate. The same 2 mg approved dose applies, but initiating at a lower monitoring intensity, checking IGF-1 at 6 weeks instead of 3 months, makes sense given the more pronounced somatopause and greater sensitivity to fluid and glucose effects at this age. [1, 2]

Activity expectations for adults aged 75 and older should account for reduced maximal aerobic capacity. The American College of Sports Medicine notes that VO2 max declines approximately 10% per decade after age 25, such that a 75-year-old has roughly 40-50% of the aerobic capacity of a 25-year-old. [4] Targets of 100-120 minutes per week of moderate-intensity walking or water-based exercise, rather than the full 150-minute target, may be more achievable and safer as a starting point, with gradual progression.

Resistance training in this sub-group should begin with bodyweight or very light resistance band exercises before progressing to free weights or machines. Chair-based exercises are acceptable starting points for patients with significant deconditioning or orthopedic limitations. The goal of preserving functional independence, specifically the ability to perform activities of daily living without assistance, is a more clinically meaningful outcome than lean-mass grams gained. [6]

Key Clinical Instruction

Before writing an activity prescription for any geriatric patient starting tesamorelin, obtain a baseline IGF-1 using an age-adjusted reference range, complete a CDC STEADI fall-risk screen, and document fasting HbA1c. These three data points, collected before injection one, define whether the patient starts with low-impact ambulation and progresses, or requires additional evaluation first. Repeat IGF-1 at 6 weeks after exercise initiation to detect additive GH-axis stimulation from combined drug and exercise effects.